Third Harmonic Bio Inc. (THRD): Price and Financial Metrics

Third Harmonic Bio Inc. (THRD): $4.04

-0.03 (-0.74%)

POWR Rating

Component Grades













Add THRD to Watchlist
Sign Up

Industry: Biotech



in industry

THRD Stock Price Chart Interactive Chart >

Price chart for THRD

THRD Price/Volume Stats

Current price $4.04 52-week high $24.59
Prev. close $4.07 52-week low $3.75
Day low $3.97 Volume 98,400
Day high $4.15 Avg. volume 147,234
50-day MA $4.25 Dividend yield N/A
200-day MA $0.00 Market Cap 163.80M

THRD Latest News Stream

Event/Time News Detail
Loading, please wait...

THRD Latest Social Stream

Loading social stream, please wait...

View Full THRD Social Stream

Latest THRD News From Around the Web

Below are the latest news stories about THIRD HARMONIC BIO INC that investors may wish to consider to help them evaluate THRD as an investment opportunity.

The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drug

Gene therapy firm bluebird bio can move forward with a study designed to test the drug lovo-cel in pediatric patients with sickle-cell disease

Yahoo | December 22, 2022

Why Is Third Harmonic Bio (THRD) Stock Down 75% Today?

THRD stock investors are clearly disappointed after Third Harmonic Bio discontinued its clinical study over safety concerns.

David Moadel on InvestorPlace | December 15, 2022

Third Harmonic Bio Stock Plummets After Trial Discontinuation On Safety Concerns

Third Harmonic Bio Inc (NASDAQ: THRD) will discontinue the ongoing Phase 1b study of THB001 in chronic inducible urticaria, after observing asymptomatic liver transaminitis in two subjects enrolled in the first dose cohort of 200mg BID. Chronic inducible urticaria is a common inflammatory skin condition characterized by the recurrence of itchy wheals and/or angioedema. The company is initiating nonclinical studies to elucidate the mechanism for the observed transaminitis, which was not predicted

Yahoo | December 15, 2022

We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | December 15, 2022

Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria

-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID -- Evidence of clinical activity observed; full data set to be presented at upcoming scientific conference -- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharm

Yahoo | December 15, 2022

Read More 'THRD' Stories Here

THRD Price Returns

1-mo -6.26%
3-mo -2.18%
6-mo -75.88%
1-year N/A
3-year N/A
5-year N/A
YTD -6.05%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6974 seconds.